Disclaimer: The manuscript and its contents are confidential, intended for journal review purposes only, and not to be further disclosed.

URL: http://hype-submit.aha-journals.org

Title: Effects of Sacubitril/valsartan versus Olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER* Study

Manuscript number: HYPE201608556R2

Author(s): Bryan Williams, University College London
          John Cockcroft, Cardiff Metropolitan University
          Kazuomi Kario, Jichi Medical University School of Medicine
          Dion Zappe, Novartis Pharmaceuticals
          Patrick Brunel, Novartis Clinical Development, Basle
          Qian Wang, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
          Weinong Guo, Novartis Pharmaceuticals Corporation
Effects of Sacubitril/valsartan versus Olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER* Study

Bryan Williams¹, John R Cockcroft², Kazuomi Kario³, Dion H Zappe⁴, Patrick C Brunel⁵, Qian Wang⁴, Weinong Guo⁶

Affiliations:

¹Department of Cardiovascular Sciences, University College London (UCL), London and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK;
²Department of Cardiology, University of Cardiff, Wales, UK;
³Jichi Medical School, Tochigi, Japan;
⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
⁵Novartis Pharma AG, Basel, Switzerland
⁶Beijing Novartis Pharma Co. Ltd. Shanghai, China

Address for correspondence:
Bryan Williams MD,
Chair of Medicine - UCL Institute of Cardiovascular Science
Maple House, First Floor Suite A,
Tottenham Court Road
London, W1T 7DN
United Kingdom
Tel: +44 (0)20 7679 6639
bryan.williams@ucl.ac.uk

*PARAMETER, Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly study

1
Short title: LCZ696 vs. Olmesartan in hypertension

Word count (including references, figures and legends): 6376

Word count of the abstract: 246

Total number of figures: 4

Total number of tables: 3
ABSTRACT

Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin-receptor-neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure (PP) >60 mmHg, indicative of arterial stiffness. Patients [N=454; mean age, 67.7 years; mean seated (ms) systolic BP (SBP), 158.6 mmHg; msPP, 69.7 mmHg] were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force-titrated to double the initial doses after 4 weeks, prior to primary assessment at 12 weeks. The study extended double-blind treatment for 12–52 weeks, during which amlodipine (2.5–5 mg), subsequently hydrochlorothiazide (6.25–25 mg) were added-on for patients not achieving BP-target (<140/90). At Week-12, sacubitril/valsartan reduced central aortic systolic pressure (CASP; primary assessment) greater than olmesartan by −3.7 mmHg (P=0.010), further corroborated by secondary assessments at Week-12 (central aortic PP, −2.4 mmHg, P<0.012; mean 24-hour ambulatory brachial SBP and CASP, −4.1 mmHg and −3.6 mmHg, respectively, both P<0.001). Differences in 24-hour ambulatory pressures were pronounced during sleep. After 52 weeks, BP parameters were similar between treatments, however, (P<0.002) more patients required add-on antihypertensive therapy with olmesartan (47%), versus sacubitril/valsartan (32%) (P<0.002). Both treatments were equally well-tolerated. The PARAMETER study, for the first time, demonstrated superiority of sacubitril/valsartan versus olmesartan in reducing clinic and ambulatory central aortic and brachial pressures in elderly patients with systolic hypertension and stiff arteries.
Keywords: Systolic hypertension, elderly, sacubitril/valsartan, olmesartan, central aortic systolic pressure
INTRODUCTION

Systolic hypertension and increased pulse pressure (PP) are indicative of arterial ageing and large artery stiffening,\textsuperscript{1, 2} which can predict incident cardiovascular (CV) disease, stroke, chronic kidney disease (CKD), and heart failure (HF).\textsuperscript{3-10} The correlation is even stronger with 24-hour ambulatory blood pressure (BP), particularly, with elevated nocturnal BP.\textsuperscript{11-15} Large artery stiffening with age impairs ventricular:vascular coupling by increasing characteristic impedance, the pressure required to generate blood flow. This explains the disproportionate rise in systolic pressure and PP with ageing and the increased load on the ventricle as a major risk factor for HF development, specifically HF with preserved ejection fraction (HFpEF).\textsuperscript{16-19}

Arterial stiffening also leads to an accelerated rise in central aortic systolic and pulse pressure relative to brachial pressures leading to reduced aortic:brachial pressure pulse amplification.\textsuperscript{20} Reducing systolic BP with antihypertensive therapies in elderly patients is associated with prominent reductions in morbidity and mortality due to CV disease, stroke and HF.\textsuperscript{21-24} Emerging evidence suggest reductions in central aortic systolic pressure (CASP) and/or central aortic pulse pressure (CAPP) relative to brachial BP reductions could be beneficial as they are better indicators of left ventricular loading, systemic exposure to pressure and consequently, a better predictor of CV disease risk.\textsuperscript{25-27}

However, antihypertensive therapies can have differential effects on central aortic pressures, despite similar effects on brachial BP.\textsuperscript{28, 29} In view of the disproportionate elevation of central aortic pressures in patients with systolic hypertension and stiffened arteries, we were interested to determine whether the novel angiotensin-receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696) would be more effective than conventional renin-angiotensin
system (RAS) blockade with an angiotensin receptor blocker (ARB), olmesartan, in reducing CASP and CAPP.

Sacubitril/valsartan (LCZ696) combines the actions of an ARB, valsartan, with a neprilysin (NEP) inhibitor,\textsuperscript{30} sacubitril. NEP is a neutral endopeptidase that degrades a number of potentially beneficial vasoactive peptides, including natriuretic peptides, bradykinin, and adrenomedullin. Inhibition of NEP potentiates the action of these peptides and we thus hypothesized, that NEP inhibition simultaneous with angiotensin receptor blockade, had the potential to counteract some of the mechanisms contributing to arterial stiffening in patients with systolic hypertension and could provide more effective lowering of central aortic pressures than an ARB alone.

This hypothesis was supported by two key observations that sacubitril/valsartan was more effective at lowering seated and ambulatory brachial BP and PP than an ARB alone,\textsuperscript{31, 32} and greater improvements in aortic characteristic impedance and greater reductions in aortic pressures in a previous study with an angiotensin converting enzyme (ACE)/NEP inhibitor (omapatrilat) compared with enalapril.\textsuperscript{16} Despite the clinical promise, omapatrilat was withdrawn due to safety concerns including increased risk of angioedema associated with the ACE-inhibitor component, which was seemingly potentiated by the NEP inhibition. Nevertheless, the potential benefit of dual RAS/NEP inhibition on aortic pressures and haemodynamics was suggested. More substantial support for the hypothesis came from PARADIGM-HF study, wherein sacubitril/valsartan showed superior clinical benefits to RAS blockade alone (enalapril) in reducing CV death and HF hospitalization in patients with HF and a reduced ejection fraction (HFrEF).\textsuperscript{33}
The Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study was thus designed to assess both the short- and long-term effects (12 and 52 weeks) of sacubitril/valsartan in comparison with ARB, olmesartan, on CASP and other measures of central haemodynamics and arterial stiffness in elderly patients with an elevated systolic BP (SBP) and an increased PP, indicative of increased arterial stiffness.

METHODS

Study design and patients

The PARAMETER study design have been described in detail previously.34 In brief, the PARAMETER study was a multi-center, randomized, double-blind, active-controlled, parallel-group, 52-week study conducted in 12 countries (Argentina, Colombia, France, Germany, Greece, Italy, Japan, Korea, Russia, Spain, Taiwan, and the USA) at 48 research sites (see online supplement 1 for study site details). The study comprised a screening period, a 3-4-week placebo run-in, and an initial double-blind monotherapy treatment period (sacubitril/valsartan versus olmesartan) of 12 weeks, followed by a double-blind extension of 40 weeks, during which add-on therapy was permitted for patients not yet achieving the clinic BP treatment goal of <140/90mmHg. Patients were initially randomised to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg for 4 weeks, followed by a forced-titration to double the initial doses for the remainder of the study. After 12 weeks, patients with uncontrolled BP (mean sitting [ms] SBP >140 mm Hg and/or ms diastolic BP [msDBP] >90 mm Hg) received open-label amlodipine (2.5–5 mg) followed by hydrochlorothiazide (6.25–25 mg), as needed, at an interval of 4 weeks up to Week 24 (on-line supplement figure S1).
Study participants

The PARAMETER study recruited elderly patients (aged ≥60 years) with systolic hypertension (either untreated or treated with antihypertensive agents). Untreated patients (newly diagnosed or not treated with antihypertensive drugs for ≥4 weeks prior to screening) had an msSBP ≥150 mm Hg and <180 mm Hg at screening and randomization. Patients previously treated with antihypertensive agents prior to screening, had an msSBP ≥140 mm Hg and <180 mm Hg prior to 3 or 4 weeks of washout/placebo run-in and ≥150 mm Hg and <180 mm Hg at randomization. In addition, all patients had a PP≥60 mm Hg at randomization. Patients with malignant or severe hypertension (msDBP ≥110 mm Hg and/or msSBP ≥ 180 mm Hg), secondary causes of hypertension, history of atrial fibrillation or atrial flutter during the 3 months prior to screening, or active atrial fibrillation or atrial flutter on electrocardiogram (ECG), history of CV disease (e.g., myocardial infarction) during 12 months prior to screening, and evidence of severe renal impairment (e.g., estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m²) were excluded.

All patients provided written informed consent before starting any study-related procedure and the study protocol was approved by independent ethics committees or institutional review boards for every treatment centre and was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was registered as EUDract number 2012-002899-14 and ClinicalTrials.gov under the code NCT01692301.

Efficacy assessments
The primary assessment of the PARAMETER study was to demonstrate the superiority of sacubitril/valsartan monotherapy versus olmesartan monotherapy in reducing mean CASP after 12 weeks of treatment. Superiority testing was also pre-specified for key secondary efficacy outcomes, including the reduction in mean CAPP and mean ambulatory (ma) CASP and maSBP after 12 weeks of treatment.

Additional secondary assessments tested the superiority of the sacubitril/valsartan-based regimen over the olmesartan-based regimen for reductions in mean CASP and CAPP from baseline to Week 52 endpoint and for reductions in mean aortic pulse wave velocity (PWV) from baseline to Week 12 and 52 endpoints. The ms central aortic diastolic BP (CADP) and mean central arterial pressure (CMAP), brachial pressures (msSBP, msDBP, msPP, msMAP), and 24-hour ma central (maCASP, maCADP, maCAPP, maCMAP) and brachial pressures (maSBP, maDBP, maPP, and maMAP) were also assessed at Weeks 12 and 52 endpoints. Exploratory analyses include changes in N-terminal-pro brain natriuretic peptides (NT-proBNP) and urinary cyclic guanosine monophosphate (cGMP)/creatinine ratio from baseline and Week 12 and baseline and Week 52 endpoints.

**Haemodynamic measurements**

*Seated brachial and central aortic pressure*

Brachial BP, non-invasive central aortic pressures and carotid-femoral PWV (cf-PWV) were measured using the SphygmoCor XCEL System (AtCor Medical, Sydney, Australia). An appropriately sized brachial pressure cuff, integral to the device, was placed on the patient’s arm, over the brachial artery and the seated brachial SBP and DBP were recorded, and patient’s
brachial arterial waveform was simultaneously captured. The brachial waveform was automatically analyzed by the SphygmoCor brachial generalized transfer function (GTF) to generate a central aortic pressure waveform, and central aortic pressure indices, including CASP and CAPP.

**Carotid-femoral Pulse Wave Velocity**

The SphygmoCor XCEL system was also used to measure cf-PWV which is recognized as a clinical index of large artery stiffness.34

**Ambulatory brachial and central aortic pressures**

The 24-hour ma brachial and central aortic pressures were measured using a specialised oscillometric device, Mobil-O-Graph (IEM, Stolberg, Germany).35

**Plasma NT-proBNP and urinary cGMP measurements**

Biomarkers were analyzed at baseline, and Weeks 12 and 52 and expressed as change from baseline. Plasma NT-proBNP was measured using the Roche Elecsys proBNP assay (Roche Diagnostics GmbH, Germany); urinary cGMP/creatinine ratio was measured from the first morning-void urine using an enzyme-linked immunosorbent assay for cGMP (R & D Systems, USA) and creatinine was measured using an enzymatic method.

**Safety assessments**

Safety and drug tolerability assessments were performed throughout the study and included regular monitoring and recording of all adverse events (AEs) and concomitant medications or significant non-drug therapies. Evaluations of routine blood chemistries, blood counts with white
cell differential and urine analyses, physical examinations, ECGs, and monitoring of vital signs were also performed at regular intervals.

**Sample size estimation**

A sample size of 183 patients per group, completing the first phase of the study (12 weeks) was estimated to be required, based on the primary assessment that is the change from baseline in mean CASP at 12 weeks, under the alternative hypothesis, a treatment difference of 6.5 mmHg, assuming a standard deviation of 19 mmHg (based on previous data). This generated a sample size of 432 patients (216 per group, assuming a 15% drop-out rate) to provide 90% power to detect statistical significance ($P<0.05$, 2-sided) comparing sacubitril/valsartan treatment versus olmesartan in assessing the superiority at the Week 12 endpoint.

**Statistical analysis**

The primary assessment (change from baseline in CASP at Week 12 endpoint), was analysed using a two-way analysis of covariance (ANCOVA) model with treatment and region as factors and the baseline as a covariate in the full analysis set (FAS), which included all patients randomized for the study. Missing endpoints were imputed using last observation carried forward (LOCF).

Other secondary assessments, excluding 24-hour ambulatory assessments, were analyzed using an ANCOVA model similar to the model used for the primary variable, with corresponding baseline assessments as a covariate. For 24-hour ambulatory assessments, a two-way repeated-measures analysis of covariance model was used. The model included treatment, region, and post-dosing hours (1 through 24 hours) as factors, corresponding baseline assessment as
covariate, and treatment by post-dosing-hour interaction term. All analyses were conducted using FAS. Multiplicity adjustment for the secondary endpoints was not considered, thus all statistical tests were made at a two-sided significant level of 0.05.

The post-hoc descriptive statistics were provided for PWV and clinic SBP. The PWV data at 12 and 52 weeks for each quartile (using baseline PWV quartile as cut-off point) were analyzed using the similar ANCOVA model with treatment, region, and baseline assessment included. Only completers were included in the analyses and missing PWV data at Week 12 or 52 were not imputed.

Mean (±standard error) changes from baseline are presented for brachial and central clinic pressures (msSBP, msDBP, msPP, msMAP, and CMAP) and ambulatory brachial and central pressures (maMAP, maCADP, maCAPP, and maCMAP) at Weeks 12 and 52. Nighttime (10pm to 6am) and daytime (6 am to 10pm) means for ambulatory SBP and aortic SBP were calculated. Mean values are presented for quartile changes in PWV, with particular focus on PWV, CASP, and msSBP in the upper PWV quartile at Weeks 12 and 52. Percentage reduction in geometric mean (95% confidence interval [CI]) is presented for biomarkers. The last observation was carried forward and not imputed for missing endpoint. Safety is presented as counts and frequency. SAS 9.4 was used for the analysis (SAS Institute Inc., Cary, NC).

RESULTS

Patient demographics

A total of 454 patients were randomized to receive sacubitril/valsartan (n=229) or olmesartan (n=225). Of these, a total of 403 (88.8%) patients completed 12 weeks and 367 (80.8%) patients
completed 52 weeks, with the major reason for study discontinuation being patient/guardian
decision followed by AEs (Figure 1). The demographics and baseline characteristics of the
randomised patients were well balanced between the two treatment regimens (Table 1). Overall,
52% were males and the mean age was 67.7 years, 13% patients aged ≥75 years, 64.3% White
Caucasian, 13.5% Asian, and 8.5% Black African, 35.5% had body mass index (BMI) ≥35
kg/m², 99% were previously treated for hypertension with a mean duration of hypertension of
11.9 years, and only 4 patients were hypertension-treatment-naïve, and 28.5% had type 2
diabetes. The most common antihypertensive medications used by the patients prior to the study
were; angiotensin receptor blockers (27.8%), ACE inhibitors (27.5%), beta blockers (11.0%),
dihydropyridine calcium channel blockers (24.2%) and thiazides diuretics (17.6%). The other
medications used by more than 10% of the total study population included HMG CoA reductase
inhibitors (38.8%), biguanides (i.e. metformin) (22.0%) and acetylsalicylic acid (aspirin)
(23.1%). 67.0%, were never smokers, 11.9% were current smokers and 21.1% were former
smokers. The mean eGFR was 80 ml/min/1.73m². The baseline brachial BP was 158.6/88.9
mmHg, with a PP of 69.7 mmHg, with a corresponding baseline CASP of 144.4 mmHg and
CAPP of 54.4 mmHg. The baseline PWV was 10.2 m/second.

Clinic central and brachial pressures

The mean reductions in CASP after 12 weeks of treatment from baseline, the primary
assessment, was −12.6 mmHg (95% CI: −14, −10.1) with sacubitril/valsartan and −8.9 mmHg
(95% CI: −11.1, −6.7) with olmesartan. The least squares mean (LSM) reductions in CASP
(primary endpoint) were superior with sacubitril/valsartan versus olmesartan with a between-
treatment difference of −3.7 mmHg (95% CI: −6.4, −0.9 mmHg, \( P=0.01 \); Figure 2).
After 12 weeks of treatment the LSM reductions in CAPP (key secondary outcome) were superior with sacubitril/valsartan versus olmesartan with a between-treatment difference of −2.4 mmHg ($P=0.01$; Figure 2). Similarly, sacubitril/valsartan lowered mean msSBP, and msPP to a greater extent than olmesartan at Week 12 endpoint (Table 2). In contrast, no difference was observed between treatments with regard to the change in CADP or msDBP from baseline to Week 12.

**Ambulatory central and brachial pressures**

The LSM reductions in mean 24-hour ambulatory brachial and central aortic systolic pressures were significantly greater with sacubitril/valsartan versus olmesartan after 12 weeks of treatment with a between-treatment difference of $-4.1$ mmHg ($P<0.001$) for maSBP and $-3.4$ mmHg ($P<0.001$) for maCASP (Table 2). The hourly brachial and central systolic pressures over 24 hours at Week 12 are presented in Figure 3. It is notable that the between treatment differences in mean 24-hour CASP and SBP are predominantly due to more effective reductions in both pressures during the nocturnal period, presumably during sleep. Nighttime (10 pm to 6 am) reductions in maCASP ($-5.2$ mmHg) and maSBP ($-5.9$ mmHg) were significantly ($P<0.001$) greater with sacubitril/valsartan compared with olmesartan with the greatest differences in the early morning hours (2 am to 6 am) in maCASP ($-6.3$ mmHg) and maSBP ($-6.9$ mmHg). Similarly, greater LSM reductions in maDBP, maPP, maMAP, maCADP, maCAPP and maCMAP ($p<0.001$) were observed with sacubitril/valsartan than with olmesartan at Week 12 endpoint (Table 2). BP control rates were also greater with sacubitril/valsartan (54.0%) compared with olmesartan (34.7%) at Week 12 ($P<0.001$).
Add-on therapy from Week 12 to 52

The requirement of an add-on antihypertensive therapy was significantly lower in patients treated with sacubitril/valsartan versus olmesartan ($P<0.002$) from Weeks 12 to 52. In the sacubitril/valsartan group, greater proportion of patients remained on monotherapy compared with that of the olmesartan group (68% versus 53%). Add-on amlodipine (+/− HCTZ) was required in 74 (32%) patients in the sacubitril/valsartan group and in 105 (47%) patients in the olmesartan group.

Brachial and central aortic pressures at Week 52

No significant differences were observed in any BP parameters (seated, ambulatory, brachial, or central) between the treatments at Week 52, although greater proportion of patients received add-on antihypertensive therapy in the olmesartan group (Table 2 and Figure 2). As a result BP control rates were not different at the end of the study between sacubitril/valsartan (58.8%) and olmesartan (57.0%).

Plasma and urinary biomarkers

Plasma NT-proBNP was elevated at baseline (overall geometric mean was 90 pg/mL). The reduction in the geometric mean plasma NT-proBNP from baseline to Week 12 (online supplement Figure S2A) was greater in patients treated with sacubitril/valsartan (34%) compared with olmesartan (20%), the difference of which was attenuated by Week 52. An increase in the geometric mean urine cGMP/creatinine ratio from baseline to Week 12 was observed, which persisted at Week 52, in the sacubitril/valsartan treated patients, consistent with its mechanism of action. No change in urinary cGMP was observed in patients treated with olmesartan at Week 12 or Week 52 (online supplement Figure S2B).
Post hoc analysis of PWV and msSBP at Weeks 12 and 52

The LSM reductions in PWV observed with both sacubitril/valsartan and olmesartan from baseline at Weeks 12 and 52 were similar for each treatment (on-line supplement Figure S3A). The changes in PWV for each treatment stratified by quartiles of baseline PWV are shown in the on-line supplement Figure S4. A possible trend of greater reduction in PWV with sacubitril/valsartan prompted a post hoc analysis of the impact of both treatments on PWV in the subgroup of patients at the upper quartile of baseline PWV (mean 12.9 m/second), indicating stiffest arteries. This post hoc analysis (on-line supplement Figure S3B) showed a non-significant trend of greater LSM reductions in PWV in the sacubitril/valsartan group versus olmesartan group at Week 12 endpoint (between-treatment difference, −0.61 m/sec), which was increased by Week 52 (between-treatment difference, −0.99 m/sec).

A post hoc analysis of SBP in the subgroup of patients in the upper quartile of PWV showed 2-fold greater reductions in CASP and msSBP with sacubitril/valsartan versus olmesartan than that was observed in the overall treatment groups (Table 2), with a between-treatment difference of −6.0 and −7.7 mmHg and −2.3 and −2.4 mmHg, at Weeks 12 and 52, respectively, versus −3.7 and −3.6 mmHg and −1.5 and −1.2 mmHg in the overall treatment groups (on-line supplement Figure S3C-D).

Clinic and ambulatory heart rate

Treatment with both sacubitril/valsartan and olmesartan showed no changes from baseline mean sitting (~71 bpm) or ambulatory heart rate (~71 bpm) both at Week 12 and 52 endpoints. The 24-hour ambulatory heart rate followed a similar circadian pattern as BP with no differential
treatment effect at daytime or nighttime and with similar reductions in heart rate during the nighttime period (~8 bpm).

Safety assessments

Treatments with both sacubitril/valsartan and olmesartan were generally well tolerated. The incidence of AEs was slightly higher in the sacubitril/valsartan-based regimen (57.6%) compared with the olmesartan-based regimen (53.8%), with nasopharyngitis being the most common AE. The overall incidence of serious AEs (SAEs) was low and similar between the sacubitril/valsartan (7%) and olmesartan-based regimen (5.8%; Table 3). AEs, SAEs, and drug-related AEs leading to the study discontinuations were similar in both treatment groups. Mild angioedema (mild tongue swelling) was reported in one patient in the sacubitril/valsartan group during Week 48, which did not require study drug interruption or hospitalization and resolved by the end of the study. Two deaths (one due to cardiorespiratory arrest and other due to respiratory failure) were reported in the olmesartan group and one death due to myocardial infarction was reported in the sacubitril/valsartan group.

DISCUSSION

The PARAMETER study, for the first time, shows the effect of sacubitril/valsartan on central aortic pressures and demonstrates the superiority of sacubitril/valsartan in lowering CASP and CAPP compared with conventional RAS blockade with the ARB olmesartan, after 12 weeks of treatment. Sacubitril/valsartan also lowered brachial SBP and PP more effectively than olmesartan (online supplement Figure S5), which is consistent with previously published studies.
comparing the effect of sacubitril/valsartan with an ARB on brachial BP and PP. This study also utilized new technology to measure 24-hour ambulatory central aortic pressures non-invasively alongside conventional 24-hour ambulatory brachial BP. Sacubitril/valsartan was superior to olmesartan at lowering 24-hour ambulatory CASP and brachial SBP, with the differences predominantly accounted by more effective lowering of nocturnal CASP and SBP with sacubitril/valsartan. To our knowledge, this is the first time a drug treatment has been shown to be especially effective at reducing nocturnal blood pressure. This is important because nocturnal pressure is most strongly associated with CV risk, and CASP has been shown to exhibit less of a nocturnal reduction relative to brachial pressure. This effect of sacubitril/valsartan on nocturnal pressure might have particular relevance in reducing the risk in people with stiffened arteries, such as elderly patients, those with diabetes and patients with CKD, all of whom tend to have a blunted nocturnal pressure dip. A characteristic of these patients is sodium retention and it is conceivable that the greater reduction in nocturnal BP with sacubitril/valsartan may be due to the diuretic action of NEP inhibition. A pharmacokinetic explanation is unlikely because the patients consumed their medication in the morning and the effect on nocturnal BP was towards the end of the dosing interval and when the patients were at steady state after 12 weeks treatment.

The study particularly focused on elderly patients with stiffened arteries as indicated by their elevated brachial PP (mean at baseline ~70 mmHg) and PWV (mean at baseline 10.2 m/second) in addition to a high SBP relative to DBP and often isolated systolic hypertension. Such patients are at highest risk of CV events, stroke and HF and have disproportionate increases in their central aortic pressures relative to brachial pressure. Sacubitril/valsartan had a greater BP
lowering effect on central and brachial SBP and PP, relative to DBP or CADP (Table 2). This is important for a number of reasons: (i) it mitigates against frequently quoted concerns about excessive lowering of DBP when treating isolated systolic hypertension, that could lead to compromised myocardial perfusion,\(^2,\,37\); (ii) this may also be important in treating patients with HFP EF who frequently have existing or antecedent systolic hypertension, stiff arteries, and a wide PP.\(^17,\,19\) The impact of sacubitril/valsartan on clinical outcomes in patients with HFP EF is currently being investigated in the PARAGON-HF study (https://clinicaltrials.gov/ct2/show/NCT01920711); (iii) this finding also suggests an arterial ‘de-stiffening’ effect associated with BP-lowering in patients with systolic hypertension and an improvement in ventricular:vascular coupling and a reduction in characteristic impedance, such that aortic flow is maintained at a lower aortic PP and with less left ventricular work. Prior studies with dual RAS/NEP inhibition with omapatrilat support this interpretation.\(^16\) A greater improvement in ventricular:vascular coupling with sacubitril/valsartan is supported by the greater reduction in NT-pro BNP (i.e. BNP release in response to cardiac wall stress) than olmesartan at Week 12 of the study (figure 4). Similar superior reductions in NT-pro BNP with sacubitril/valsartan versus RAS blockade alone (enalapril) have also been observed in the studies in patients with HF.\(^38,\,39\)

We also demonstrated a significant increase in urinary cGMP levels with sacubitril/valsartan treatment (+45% at Week 12), which persisted throughout the study (+36% at Week 52), the change which was not observed with olmesartan. This increase in cGMP is consistent with the mechanism of action of the NEP inhibition component of sacubitril/valsartan, which decreases
the breakdown of potentially beneficial vasoactive peptides such as atrial natriuretic peptide, BNP and bradykinin, which activate guanlyate cyclase to produce cGMP.\textsuperscript{30}

We measured cf-PWV at baseline and Week 12 and 52, to establish whether there were differences in aortic stiffness with treatment and between treatments. Cf-PWV is strongly influenced by BP,\textsuperscript{40} and as expected cf-PWV was reduced by both treatments after 12 weeks of treatment and further reduced by Week 52, when the BP difference between treatment arms was more closely matched. We found considerably more within-patient variance than expected in cf-PWV measurements with the technology used in this study (Sphygmocor X-CELI, AtCor, Australia), thereby reducing statistical power to compare the effects of sacubitril/valsartan versus olmesartan on aortic stiffness.

Beyond the initial 12 weeks of the study, add-on antihypertensive therapy was allowed until the study end at 52 weeks for those patients not achieving BP target (clinic BP <140/90 mmHg). By Week 52, the differences in brachial and central aortic pressures between treatments had diminished, in large part due to the significantly greater use of add-on therapy to achieve the BP goal in the patients treated with olmesartan. This data reinforces the superior BP-lowering efficacy of sacubitril/valsartan compared with RAS blockade alone.

Both treatments were similarly well tolerated throughout the 52 weeks of the study with a low rate of AEs (~7%) and SAEs (~2.6%), consistent with previously reported data for sacubitril/valsartan in patients with HFrEF.\textsuperscript{33} Moreover, unlike prior concerns of angioedema with dual RAS/NEP inhibition with omapatrilat (which included ACE-inhibition), excess cough
was not reported, and mild angioedema (mild tongue swelling) was reported in only one patient (African American patient from the U.S.) in the sacubitril/valsartan group during Week 48 of the study. No complications or hospitalisation were reported with sacubitril/valsartan in our study. With regard to changes in plasma potassium levels, at week 12 the change in potassium with LCZ696 or olmesartan was +0.1 mmol/L and +0.7 mmol/L respectively. At week 52 the change in potassium with LCZ696 or olmesartan was +0.3 mmol/L and +0.8 mmol/L respectively. More patients experienced serum potassium >5.5 mmol/L during with LCZ696 group (8.0%) compared with the olmesartan group (5.9%), with more severe cases (serum potassium ≥6.0 mmol/L) in the olmesartan group (2.7%) versus the LCZ696 group (0.9%).

The PARAMETER study has a number of strengths; (i) the first 12 weeks of the study allowed direct comparison of sacubitril/valsartan with the ARB olmesartan, uncontaminated by add-on therapies and showed superiority of sacubitril/valsartan with regard to central aortic and brachial BP reduction; (ii) BP was comprehensively evaluated with 24-hour ambulatory BP monitoring and 24-hour ambulatory CASP, which confirmed superior BP lowering of sacubitril/valsartan on both parameters and demonstrated novel BP lowering effects of sacubitril/valsartan on nocturnal BP; (iii) olmesartan is an ARB with a long duration of action which has previously been shown to reduce arterial stiffness and central aortic pressure \(^{41,42}\) and was administered at the maximal recommended dose to ensure an optimal comparator\(^{43}\); (iv) the extension of the study to 52 weeks allowed the evaluation of effects of add-on therapies recommended by all international hypertension guidelines including a calcium channel blocker and/or a thiazide-type diuretic.\(^{44}\) This phase of the study confirmed that less add-on therapy was required to improve BP control with sacubitril/valsartan versus olmesartan; and (v) finally, the study included different ethnic
groups and people with diabetes and no heterogeneity of effect was noted on the primary outcome across groups.

The study also has some limitations; (i) the study was not designed to, and was too short to evaluate the effects of sacubitril/valsartan on clinical outcomes. Nevertheless, the magnitude of BP reduction achieved, has previously been shown to have a major beneficial impact of CV outcomes, stroke and HF in patients with systolic hypertension.\textsuperscript{21-23} In this regard, based on a recent comprehensive analysis of BP lowering on clinical outcomes,\textsuperscript{45} the magnitude of systolic BP fall with sacubitril/valsartan in the first 12 weeks, if maintained over the long-term, could result in a reduced risk of major CV disease events and coronary heart disease by \(\sim 25\%\), HF by \(\sim 30\%\), and all-cause mortality by almost 20%; (ii) although we set out to examine the effects of both treatments on ameliorating aortic stiffness (cf-PWV), the methodology we used was not as robust as expected, and further studies, ideally using magnetic resonance imaging (MRI) are required to determine if sacubitril/valsartan has any specific BP-independent beneficial effects on ventricular:vascular coupling, aortic characteristic impedance, and distensibility. However, the greater reduction in NT-proBNP and pulse pressure observed with sacubitril/valsartan versus olmesartan indicates a ‘de-stiffening’ effect of sacubitril/valsartan and a reduction in cardiac wall stress.

**PERSPECTIVE**

The PARAMETER is the first randomized controlled trial demonstrating the ability of dual ARB/NEP inhibition with sacubitril/valsartan to reduce central aortic pressures (especially CASP and CAPP) more effectively than an ARB, in high-risk elderly patients with systolic hypertension and an increased PP, indicative of arterial stiffness. These results suggest that
sacubitril/valsartan provides beneficial effects on central aortic hemodynamics and function that could provide a therapeutic advantage beyond those observed with RAS blockade alone.

Acknowledgments:
The authors acknowledge support of Dr Sreedevi Boggarapu (Novartis Healthcare Pvt. Ltd, Hyderabad, India) for editorial support. They also thank all the clinical investigators and study coordinators at the participating centers and all the patients who participated in the study. Bryan Williams is a National Institute for Health Research (NIHR) Senior Investigator and his research is supported by the NIHR University College London Hospitals Biomedical Research Centre.

Source of funding:
This study was an investigator-designed and investigator-led study, funded by Novartis Pharmaceuticals Corporation.

Conflicts of Interest / Disclosures:
BW has received honoraria for conference lectures from Novartis and Daiichi Sankyo, JRC and KK have received fees for consultancy from Novartis, DHC, PCB, QW and WG are employees of Novartis Pharmaceuticals, Inc.
References


37. Williams B. Hypertension and the "j-curve". *Journal of the American College of Cardiology.* 2009;54:1835-1836

neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation.* 2015;131:54-61


42. Ruilope LM. Fixed-combination olmesartan/amlopidine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. *Journal of Clinical Hypertension (Greenwich, Conn).* 2015, 18: 528-535.


Novelty and Significance:

What is New: This is the first randomized controlled trial comparing an Angiotensin Receptor Blocker /Neutral Endopeptidase inhibitor (ARB/NEPi) (Sacubitril/valsartan) versus a conventional an ARB (Olmesaratan) on central aortic pressures and hemodynamics in elderly patients with stiff arteries and systolic hypertension.

What is relevant: Controlling systolic hypertension is an unmet need in elderly patients and central aortic systolic and pulse pressures are disproportionately elevated in these patients.

Summary: The ARB/NEPi was significantly more effective at lowering brachial and central aortic systolic and pulse pressures than conventional renin angiotensin system blockade with an ARB.
Legends

**Figure 1.** Patient disposition

*All randomized patients

AE, adverse event

**Figure 2.** Reduction in CASP and pulse pressure from baseline at week 12 and 52

‡CASP was the primary efficacy

CASP, central aortic systolic pressure; CAPP, central aortic pulse pressure

**Figure 3.** Peripheral and central 24-hourly mean ambulatory SBP: at Week 12 (A) and Week 52 (B) endpoints

SBP, systolic blood pressure
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>LCZ696 (N=229)</th>
<th>Olmesartan (N=225)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>68.2 (5.73)</td>
<td>67.2 (5.97)</td>
<td>0.068</td>
</tr>
<tr>
<td>Age group, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60 and &lt;65 years</td>
<td>68 (29.7)</td>
<td>91 (40.4)</td>
<td>0.056</td>
</tr>
<tr>
<td>≥65 and &lt;75 years</td>
<td>129 (56.3)</td>
<td>107 (47.6)</td>
<td></td>
</tr>
<tr>
<td>≥75 years</td>
<td>32 (14.0)</td>
<td>27 (12.0)</td>
<td></td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>119 (52.0)</td>
<td>118 (52.4)</td>
<td>0.919</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>148 (64.6)</td>
<td>144 (64.0)</td>
<td>1.000</td>
</tr>
<tr>
<td>Black</td>
<td>20 (8.7)</td>
<td>19 (8.4)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>31 (13.5)</td>
<td>31 (13.8)</td>
<td></td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>28.6 (4.47)</td>
<td>29.1 (4.9⁵)</td>
<td>0.128</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>65 (28.4)</td>
<td>65 (28.9)</td>
<td>0.905</td>
</tr>
<tr>
<td>Duration of hypertension, years°</td>
<td>11.4 (8.93)</td>
<td>12.3 (9.98)</td>
<td>0.321</td>
</tr>
<tr>
<td>Proportion of patients with prior history of hypertension (%)</td>
<td>99.6</td>
<td>98.7</td>
<td>0.307</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>BP and PP, mmHg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASP‡</td>
<td>144.0 (12.65)</td>
<td>144.9 (12.63)</td>
<td>0.444</td>
</tr>
<tr>
<td>CADP‡</td>
<td>89.0 (9.58)</td>
<td>91.1 (10.24)</td>
<td>0.025</td>
</tr>
<tr>
<td>CAPP‡</td>
<td>55.0 (11.86)</td>
<td>53.8 (12.95)</td>
<td>0.311</td>
</tr>
<tr>
<td>CMAP‡</td>
<td>109.9 (10.25)</td>
<td>111.5 (9.89)</td>
<td>0.095</td>
</tr>
<tr>
<td>msSBP‡</td>
<td>158.4 (13.41)</td>
<td>158.8 (13.48)</td>
<td>0.788</td>
</tr>
<tr>
<td>msDBP‡</td>
<td>87.8 (9.72)</td>
<td>89.9 (10.38)</td>
<td>0.027</td>
</tr>
<tr>
<td>msPP‡</td>
<td>70.6 (13.00)</td>
<td>68.8 (14.17)</td>
<td>0.171</td>
</tr>
<tr>
<td>msMAP‡</td>
<td>111.4 (9.24)</td>
<td>112.9 (9.37)</td>
<td>0.085</td>
</tr>
<tr>
<td>maCASP§</td>
<td>133.0 (13.63)</td>
<td>132.9 (12.11)</td>
<td>0.935</td>
</tr>
<tr>
<td>maCADP§</td>
<td>87.6 (10.14)</td>
<td>88.2 (9.44)</td>
<td>0.596</td>
</tr>
<tr>
<td>maCAPP§</td>
<td>45.3 (9.79)</td>
<td>44.6 (9.80)</td>
<td>0.523</td>
</tr>
<tr>
<td>maCMAP§</td>
<td>102.8 (10.45)</td>
<td>103.1 (9.33)</td>
<td>0.753</td>
</tr>
<tr>
<td>maSBP§</td>
<td>145.3 (14.01)</td>
<td>144.6 (12.83)</td>
<td>0.656</td>
</tr>
<tr>
<td>maDBP§</td>
<td>85.7 (10.11)</td>
<td>86.6 (9.42)</td>
<td>0.431</td>
</tr>
<tr>
<td>Parameter</td>
<td>LCZ696 Mean ± SD</td>
<td>Olmesartan Mean ± SD</td>
<td>p-value</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------</td>
<td>----------------------</td>
<td>---------</td>
</tr>
<tr>
<td>maPP</td>
<td></td>
<td>59.6 (11.19)</td>
<td>58.0 (11.29)</td>
</tr>
<tr>
<td>maMAP</td>
<td></td>
<td>113.0 (10.69)</td>
<td>113.2 (9.59)</td>
</tr>
<tr>
<td>PWV ‡</td>
<td>10.3 (2.11)</td>
<td>10.2 (1.91)</td>
<td>0.507</td>
</tr>
<tr>
<td>msHR</td>
<td>70.4 (11.7)</td>
<td>71.2 (11.1)</td>
<td>0.413</td>
</tr>
<tr>
<td>maHR</td>
<td>71.1 (10.2)</td>
<td>71.9 (9.4)</td>
<td>0.451</td>
</tr>
<tr>
<td>eGFR (&lt;60 ml/min/1.73 m²)</td>
<td>78.9 (19.87)</td>
<td>81.5 (31.91)</td>
<td>0.306</td>
</tr>
</tbody>
</table>

Data are mean ± SD unless until specified; *n=224 for LCZ696, n=215 for olmesartan; †n=224; ‡n=226 for LCZ696, n=220 for olmesartan; §n=159 for LCZ696, n=158 for olmesartan; ¶n=164 for LCZ696, n=162 for olmesartan; ‖n=214 for both treatments

BP, blood pressure; PP, pulse pressure; CASP, central aortic systolic pressure; CADP, central aortic diastolic pressure; CAPP, central aortic pulse pressure; CMAP, central mean arterial pressure; ms, mean sitting; SBP, systolic BP; DBP, diastolic BP; ma, mean ambulatory, PWV, pulse wave velocity; HR, heart rate; eGFR, estimated glomerular filtration rate; SD, standard deviation
Table 2. Hemodynamic changes from baseline at Weeks 12 Endpoint and 52 Endpoint

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Change from baseline to Week 12</th>
<th>Change from baseline to Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LCZ696-regimen</td>
<td>Olmesartan-regimen</td>
</tr>
<tr>
<td></td>
<td>N=207</td>
<td>N=206</td>
</tr>
<tr>
<td></td>
<td>CASP</td>
<td>CADP</td>
</tr>
<tr>
<td></td>
<td>−12.6 (−14.6, −10.6)</td>
<td>−8.9 (−10.9, −6.9)</td>
</tr>
<tr>
<td></td>
<td>−16.2 (−18.1, −14.3)</td>
<td>−14.7 (−16.6, −12.8)</td>
</tr>
<tr>
<td></td>
<td>−6.1 (−7.4, −4.8)</td>
<td>−5.0 (−6.2, −3.7)</td>
</tr>
<tr>
<td></td>
<td>−8.8 (−10.1, −7.6)</td>
<td>−8.1 (−9.3, −6.9)</td>
</tr>
<tr>
<td></td>
<td>−6.4 (−7.7, −5.1)</td>
<td>−4.0 (−5.3, −2.6)</td>
</tr>
<tr>
<td></td>
<td>−7.2 (−8.5, −5.8)</td>
<td>−6.6 (−8.0, −5.3)</td>
</tr>
<tr>
<td></td>
<td>−8.5 (−10.0, −7.1)</td>
<td>−6.5 (−8.0, −5.0)</td>
</tr>
<tr>
<td></td>
<td>−10.1 (−11.7, −8.6)</td>
<td>−8.6 (−10.2, −7.1)</td>
</tr>
<tr>
<td></td>
<td>−13.7 (−15.9, −11.5)</td>
<td>−9.9 (−12.1, −7.6)</td>
</tr>
<tr>
<td></td>
<td>−17.7 (−19.8, −15.6)</td>
<td>−16.1 (−18.2, −14.0)</td>
</tr>
<tr>
<td></td>
<td>−5.9 (−7.1, −4.7)</td>
<td>−4.9 (−6.2, −3.7)</td>
</tr>
<tr>
<td></td>
<td>−8.7 (−9.9, −7.5)</td>
<td>−8.1 (−9.3, −6.9)</td>
</tr>
<tr>
<td></td>
<td>−7.7 (−9.3, −6.2)</td>
<td>−4.9 (−6.5, −3.3)</td>
</tr>
<tr>
<td></td>
<td>−8.8 (−10.4, −7.2)</td>
<td>−8.0 (−9.6, −6.4)</td>
</tr>
<tr>
<td>Variable</td>
<td>Baseline</td>
<td>Change</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td>msMAP</td>
<td>-8.5</td>
<td>-6.6</td>
</tr>
<tr>
<td>maCASP</td>
<td>-12.1</td>
<td>-8.7</td>
</tr>
<tr>
<td>maCADP</td>
<td>-7.7</td>
<td>-5.7</td>
</tr>
<tr>
<td>maCAPP</td>
<td>-4.4</td>
<td>-3.0</td>
</tr>
<tr>
<td>maCMAP</td>
<td>-9.1</td>
<td>-6.7</td>
</tr>
<tr>
<td>maSBP</td>
<td>-13.3</td>
<td>-9.1</td>
</tr>
<tr>
<td>maDBP</td>
<td>-7.4</td>
<td>-5.5</td>
</tr>
<tr>
<td>maPP</td>
<td>-5.8</td>
<td>-3.7</td>
</tr>
<tr>
<td>maMAP</td>
<td>-10.1</td>
<td>-7.1</td>
</tr>
<tr>
<td>PWV*</td>
<td>-0.7</td>
<td>-0.6</td>
</tr>
</tbody>
</table>

*PWV: Pulse Wave Velocity
Data are mean with 95% CI; *n=192 for LCZ696, n=196 for olmesartan at Week 12 endpoint; n=199 for both the treatments at Week 52 endpoint; BP, blood pressure; PP, pulse pressure; CASP, central aortic systolic pressure; CADP, central aortic diastolic pressure; CAPP, central aortic pulse pressure; CMAP, central mean arterial pressure; ms, mean sitting; SBP, systolic BP; DBP, diastolic BP; ma, mean ambulatory; PWV, pulse wave velocity.
Table 3. Number of patients with adverse events (≥2% in any treatment group) in the double-blind period

<table>
<thead>
<tr>
<th>Variable</th>
<th>LCZ696-regimen (N=229)</th>
<th>Olmesartan-regimen (N=225)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths</td>
<td>1 (0.4)</td>
<td>2 (0.9)</td>
</tr>
<tr>
<td>SAEs</td>
<td>16 (7.0)</td>
<td>13 (5.8)</td>
</tr>
<tr>
<td>Discontinuations due to AEs</td>
<td>16 (7.0)</td>
<td>14 (6.2)</td>
</tr>
<tr>
<td>Drug-related AE discontinuations</td>
<td>6 (2.6)</td>
<td>5 (2.2)</td>
</tr>
<tr>
<td>SAE discontinuations</td>
<td>6 (2.6)</td>
<td>6 (2.7)</td>
</tr>
<tr>
<td>Any adverse event</td>
<td>132 (57.6)</td>
<td>121 (53.8)</td>
</tr>
<tr>
<td>Any adverse event reported by ≥2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>16 (7.0)</td>
<td>12 (5.3)</td>
</tr>
<tr>
<td>Headache</td>
<td>14 (6.1)</td>
<td>10 (4.4)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>12 (5.2)</td>
<td>12 (5.3)</td>
</tr>
<tr>
<td>Cough</td>
<td>10 (4.4)</td>
<td>2 (0.9)</td>
</tr>
<tr>
<td>Influenza</td>
<td>7 (3.1)</td>
<td>5 (2.2)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6 (2.6)</td>
<td>5 (2.2)</td>
</tr>
<tr>
<td>Condition</td>
<td>Study 1 (N=60)</td>
<td>Study 2 (N=200)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>edema peripheral</td>
<td>6 (2.6)</td>
<td>2 (0.9)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>6 (2.6)</td>
<td>6 (2.7)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5 (2.2)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (2.2)</td>
<td>7 (3.1)</td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (2.2)</td>
<td>2 (0.9)</td>
</tr>
<tr>
<td>Back pain</td>
<td>3 (1.3)</td>
<td>10 (4.4)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>2 (0.9)</td>
<td>5 (2.2)</td>
</tr>
</tbody>
</table>

Data are number of patients (%).
Randomized*  
N=454

LCZ696-based regimen  
N=229

Discontinuations during 52 weeks  45 (19.7%)
AEs  15 (6.6%)
Death  1 (0.4%)
Lack of efficacy  0 (0.0%)
Protocol deviation  9 (3.9%)
Patient/guardian decision  16 (7.0%)
Other  4 (1.7%)

Completed  
12 weeks: 203 (89%)  
52 weeks: 184 (80%)

Olmesartan-based regimen  
N=225

Discontinuations during 52 weeks  42 (18.7%)
AEs  12 (5.3%)
Death  2 (0.9%)
Lack of efficacy  5 (2.2%)
Protocol deviation  2 (0.9%)
Patient/Guardian decision  15 (6.7%)
Other  6 (2.6%)

Completed  
12 weeks: 200 (89%)  
52 weeks: 183 (81%)